FDA Has Accepted New Application for Psoriasis Treatment
Adults with plaque psoriasis may soon have a new oral therapy option as regulators begin review of the drug zasocitinib.
Updated on Sept. 23, 2026 in Arthritis
Live Poll
Do you believe new oral treatments are a better approach to managing plaque psoriasis symptoms?
The FDA has accepted the New Drug Application for Takeda’s oral psoriasis treatment, zasocitinib, following positive results in large-scale clinical trials. The drug is currently under review for its potential to provide a new oral option for patients, with a decision expected in early 2027.
Why it matters
The submission aims to address the significant demand for more effective, non-injectable treatment options for individuals living with plaque psoriasis. The review process marks a major step in potentially expanding the therapeutic landscape for this chronic condition.
In clinical trials involving nearly 3,000 patients, approximately 70% achieved clear or almost clear skin by week 16, with some participants seeing results as early as week 4. The findings are based on data from three pivotal Phase 3 studies.
The players
Takeda
A global pharmaceutical company headquartered in Osaka, Japan, with U.S. operations in Cambridge, Massachusetts, focused on immunology and rare diseases.
FDA
The United States regulatory agency responsible for evaluating the safety and efficacy of new medical therapies before market entry.
The details
Zasocitinib is an oral tyrosine kinase 2 (TYK2) inhibitor designed to modulate the immune response associated with skin inflammation. By targeting this specific intracellular enzyme, the drug works to disrupt the signaling pathways that contribute to the development of psoriatic plaques. Beyond plaque psoriasis, the medication is currently being studied for its potential efficacy in treating other inflammatory conditions including psoriatic arthritis and Crohn's disease.
Timeline
September 14, 2026: The FDA accepted the New Drug Application for zasocitinib.
Q1 2027: The FDA target action date for a regulatory decision.
Health Landscape
This submission represents the latest entry into the competitive tyrosine kinase 2 (TYK2) inhibitor class of medications. The drug follows an established trend in dermatology where oral, targeted therapies are being developed as alternatives to traditional injectable biologics.
If you are managing plaque psoriasis or psoriatic arthritis, keep in mind that this remains an experimental therapy awaiting regulatory approval. Discuss any changes to your long-term treatment plan with your doctor once final clinical data and availability are confirmed in early 2027.
The takeaway
The movement of this treatment through the regulatory process underscores the growing efficacy of targeted oral therapies for chronic skin conditions. Patients should continue to monitor their current symptom patterns and discuss potential new oral medications with their physician as they become available.
Further reading
For more on evolving treatment options for inflammatory joint and skin conditions, visit our Arthritis section.
More information
Review the full clinical trial study details on the official registry portal.
Source note: This article includes information reported by Drugs.
Live Poll
Do you believe new oral treatments are a better approach to managing plaque psoriasis symptoms?
